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Background: The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs)
as first-line treatment for uncomplicated malaria. Sudan revised its malaria treatment policy accordingly in 2004.
However, eight years after ACTs were introduced in Sudan the patterns of ACT prescribing practices among health
care providers remain unclear. We systematically analyzed use of ACTs in a large number of primary health facilities
and we discuss the public health implications of our findings.
Methods: This cross-sectional study was based on WHO’s guidance for investigating drug use in health facilities.
Data were collected from 40 randomly selected primary health centers in five localities in Gezira State, Sudan. The
primary outcome of the study was the proportion of patients who were adequately managed according to Sudan’s
recommended malaria treatment guidelines. Twelve drug-use indicators were used to assess key ACT prescribing
practices.
Results: One thousand and two hundred patients diagnosed with uncomplicated malaria were recruited into the
study. ACT was prescribed for 88.6%patients and artemether injections were (incorrectly) prescribed in 9.5% of cases.
Only 40.9% of patients in the study were correctly diagnosed and 26.9% were adequately managed according to
the nationally recommended treatment guidelines. Incorrect prescribing activities included failure to use generic
medicine names (88.2%), incorrect dosage (27.7%), and unexplained antibiotic co-prescription (24.2%). Dispensing
practices were also poor, with labeling practices inadequate (97.1%) and insufficient information given to patients
about their prescribed treatment (50.5%).
Conclusion: Irrational malaria treatment practices are common in Sudan. This has important public health
implications since failure to adhere to nationally recommended guidelines could play a role in the future
development of drug resistance. As such, identifying ways to improve the anti-malarial prescribing practices of
heath workers in Sudan may be a priority.
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The World Health Organization (WHO) recommends
artemisinin-based combination therapies (ACTs) as first-
line treatment for uncomplicated malaria [1,2]. ACTs
consist of two anti-malarial compounds: an artemisinin
derivative, which induces rapid reduction of parasite
load in blood over a period of days, and a partner drug,
which eradicates remaining parasites [3].
Recently, artemisinin resistance has been observed in
four Southeast Asian countries (Cambodia, Myanmar,
Thailand, and Viet Nam) [4-6]. This has been attributed
to factors including irrational prescribing practices, poor
patient compliance with prescribed regimens, improper
use of artemisinin monotherapies, and inadequate access
to quality assured forms of the drug [7-9]. Fortunately,
ACTs remain effective as long as resistance to the part-
ner drug has not developed [10]. But while resistance to
ACTs has not yet been observed, concern exists that
poor treatment practices may promote ACT resistance
in the future, a situation similar to the global spread of
chloroquine resistance that has occured [11].
In 2011, WHO encouraged the scale-up of interven-
tions to protect the efficacy of ACTs, which was sup-
ported by the release of the Global Plan for Artemisinin
Resistance Containment [8]. Currently, WHO recom-
mends five forms of ACTs: artemether-lumefantrine (AL),
artesunate-sulfadoxine/pyrimethamine (ASP), artesunate-
amodiaquine (ASAQ), artesunate-mefloquine (ASMQ), and
dihydroartemisinin-piperaquine (DHAPQ) [12]. Malaria-
endemic countries in Sub-Saharan Africa have adopted sev-
eral of these different formulations of ACTs in their
national strategies for malaria control and elimination [13].
In 2004 Sudan revised its Malaria treatment policy in
favor of use of ACTs. The nationally recommended
first- and second-line treatments are ASP and AL, re-
spectively [14,15], both of which are provided free of
charge at primary health care facilities in Sudan. Ac-
cording to national treatment guidelines in Sudan, per-
ipheral blood smears should be obtained on febrile
patients that are suspected of having malaria in order
to confirm the diagnosis before treatment (presumptive
diagnosis of malaria is no longer accepted for prescrib-
ing treatment, except in the increasingly rare event that
no laboratory facility or rapid diagnostic testing cap-
ability are available). However, some data suggest that
the malaria guidelines in Sudan are far from universally
adhered to. A cluster-sample survey conducted in 15
states in Sudan five years following ACT introduction
found that only 35% of febrile patients were treated ac-
cording to test results [16]. Another survey revealed
that the nationally recommended first-line treatment
(ASP) was prescribed in only 44% of prescriptions [17].
Eight years after introduction of public policy aimed at
harmonizing effective and appropriate anti-malarialtreatment across the country, the patterns of ACT use
in Sudan remain largely unclear.
In this study we aimed to systematically explore patterns
of ACT use among health care providers in primary health
care units in Sudan, and to assess the significance of the
findings in the context of risks for drug resistance. We
suspected that the results of this investigation could pro-
vide a useful quantitative analysis of specific ACT pre-
scribing problems that are common in Sudan, and could
potentially help to inform strategies for promoting rational
use of ACT nationally.
Methods
Study setting
This was a cross-sectional study conducted in Gezira
State, which is located in the east-central region of the
Sudan. Gezira is a large state with a total area of
27,549 km [18]. Administratively, it is divided into eight
localities, containing 65 hospitals and greater than 800
primary health care facilities.
Study population
The study population consisted of patients that sought
medical care at primary health care facilities throughout
Gezira State and who were diagnosed with uncomplicated
malaria. Uncomplicated malaria was confirmed by the
demonstration of asexual forms of the parasite in the thick
or thin peripheral blood smear or by rapid diagnostic test
in the presence of fever. We based our sampling method
and sample size calculation on guidelines published by
WHO (“How to Investigate Drug Use in Health Facilities”)
[19]. Patients were recruited through a three-step sampling
methodology in which we took advantage of existing ad-
ministrative divisions of the state and clustering at the level
of primary health centers. Firstly, five of Gezira State’s 8 lo-
calities were randomly selected for participation in the
study. Second, 40 “clusters” (i.e., primary health centers)
within those five states were randomly selected. Finally, 30
patients were recruited from each primary health center in-
cluded in the study in order to arrive at the sample size of
1,200 patients. The study took place over a 5 month period
(July-November 2011). During the study period, study
teams visited each primary health center and recruited the
first 30 consecutive patients who were diagnosed with un-
complicated malaria and who verbally consented to be in
the study. In health facilities with high patient volume, only
2–3 days were required to recruit the necessary number of
patients. In other health facilities with lower patient vol-
umes, up to 12 days were needed to recruit 30 patients di-
agnosed with uncomplicated malaria.
Data collection and analyses
Data were collected prospectively. The primary outcome
of this study was the proportion of patients who were
Table 1 Anti-malarial treatment formulations prescribed
in 40 primary health centers in Gezira State, Sudan
n %
Artesunate-sulfadoxine/pyrimethaminetablets 1,061 88.4
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mended treatment guidelines. Adequate management
was defined by patient history of fever, positive blood
smear for malaria, and first-line anti-malarial treatment
prescribed in the correct dose.
Seven core drug use indicators drawn from WHO’s pre-
scribing and patient-care indicators [19] were used to as-
sess key practices of health care providers. The prescribing
indicators were: anti-malarial prescribed in generic name,
antibiotic co-prescribed, analgesic co-prescribed, and anti-
malarial dosage form correctly written. The patient-care
indicators were: anti-malarial prescribed was fully dis-
pensed, anti-malarial adequately labeled, and patient ad-
equately informed about the prescribed anti-malarial. We
also measured an additional 5 indicators that were devel-
oped for the purpose of this study in order to evaluate es-
sential components of the nationally recommended
protocol for diagnosing and treating malaria correctly in
Sudan. These supplementary indicators were: patient his-
tory of fever, whether or not a clinical examination was
performed, blood smear evaluation, positive blood smear,
and correct diagnosis (as defined by patient history of
fever and positive blood smear).
Study staff reviewed patients’ prescriptions to collect
data relating to prescribing indicators. Exit interviews
with patients were conducted to explore patient-care
practices. Data collectors attended an intensive training
workshop prior to the start of the study to help ensure
standardized data collection. Training components in-
cluded familiarization with drug use indicators, how to
properly extract information from anti-malarial drug-
containing prescriptions, how to interview patients, and
how to record and code indicators. At study sites, data
collectors recruited patients at the pharmacy when pa-
tients came to collect their medicines following clinical
encounters. Through a verbal consent process, data col-
lectors explained the purpose and risks of the study to
patients. Those who consented to participate were
interviewed and their prescriptions were reviewed. Data
were recorded on standardized forms and coded.
Statistics
Chi-squared test was utilized to compare frequencies of
prescription, patient-care, and supplementary indicators
between types of anti-malarial medications prescribed.
Data were analyzed using SPSS 22.0 (IMB SPSS Inc.,
Chicago, IL, USA).Artemether injection 114 9.5%
Quinine injection 14 1.2%
Quinine tablets 5 0.4%
Sulfadoxine/pyrimethamine tablets 4 0.3%
Artemether-lumefantrine tablets 2 0.2%
Total 1,200 100.0%Ethical considerations
Ethical approvals for this study were obtained from Al
Neelain University Institutional Review Board, the Sudan
National Fund for Promoting Medical Services, and Gezira
State Ministry of Health. Verbal-only consent was approvedby the three boards, as it was not practical to obtain written
informed consent from all patients.
Results
The five localities within Gezira State that were ran-
domly selected for this study were Greater Medani,
Gezira South, Gezira East, Hasahisa, and Kamleen. The
names of the 40 primary health centers within these five
localities that were randomly selected for participation
are being kept anonymous to maintain confidentiality of
patients and health providers.
Of the 1,200 prescriptions reviewed, 88.6% included
ACT (Table 1). Of these, virtually all were ASP; only two
ACT prescriptions contained AL. One hundred and four-
teen (114) patients were prescribed artemether injections,
comprising 9.5% of the prescriptions. As the main focus of
this was ACT prescribing practices, we restricted subse-
quent data analysis to the 1,175 patients (98%) who were
prescribed either ASP or artemether injections.
Just fewer than 41% percent of the 1,200 patients in
the study were correctly diagnosed with uncomplicated
malaria, and 26.9% of patients were adequately managed
for uncomplicated malaria according to the nationally
recommended treatment guidelines.
The frequencies of prescribing, patient-care, and sup-
plementary indicators stratified by anti-malarial medi-
cine prescribed are presented in Tables 2, 3 and 4. Only
11.8% of prescriptions contained the generic name, and
strong evidence of association existed between prescrib-
ing in generic name and the type of anti-malarial pre-
scribed (p <0.000). Although ASP was prescribed in
greater than 90% of prescriptions, it was written generic-
ally in only 6.7% of prescriptions. It was observed that
many prescribers tended to write the informal name for
ASP (“Rajimat” which translates to “missiles” in English).
Conversely, artemether, while incorrectly prescribed, was
written generically in 58.5% of prescriptions. Nearly 25%
of prescriptions contained an antibiotic without a clear
indication for its use.
Regarding dispensing practices, the prescribed anti-
malarial was fully dispensed in the vast majority of cases,
Table 2 Prescribing indicators stratified by anti-malarial medication prescribed
ASP n (%) ART* n (%) All prescriptions n (%) 95% CI Chi-squared
p valueN = 1,061 N = 114 N = 1,175
Anti-malarial prescribed in generic name 71 (6.7%) 67 (58.8%) 138 (11.8%) 10-13.6 0.000
Antibiotic co-prescribed 248 (23.4%) 36 (31.6%) 284 (24.2%) 21.8-26.7 0.000
Analgesic co-prescribed 342 (32.2%) 84 (73.7%) 426 (36.3%) 33.6-39.1 0.065
Anti-malarial dosage form correctly written 769 (72.5%) 80 (70.2%) 849 (72.3%) 69.7-74.9 0.584
*Artemether injection.
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at the study sites. However, labeling practices were ad-
equate in only 2.9% of dispensed treatment packages.
More than half of patients were inadequately informed
about their anti-malarial treatment.
Discussion
More than eight years have elapsed since the introduc-
tion of ACT for malaria in Sudan. However, proper case
management for patients with malaria remains a chal-
lenge. In this large study of prescribing practices among
healthcare workers in Gezira State, the recommended
first-line drug was prescribed in most patients, which
would seem to indicate confidence among heath care
providers in this approach to treatment. Nevertheless,
misuse of ACTs was widespread. Artemether injections
were prescribed inappropriately, patients were not diag-
nosed according to standard guidelines, patients received
inadequate education regarding their therapy, and treat-
ment packages were poorly labeled. Overall, a minority
of patients were diagnosed and treated according to the
nationally recommended guidelines. A previous study in
Ghana showed similar results [20].
A variety of factors may explain the findings in this
study. For instance, poor supervision of health care pro-
viders, coupled with inadequate training and few oppor-
tunities for continuing education, could be a contributing
cause of irrational ACT prescribing. Patient-related factors
may also play a large role. Self-treatment of malaria is a
common practice in Sudan [21], as well as in other coun-
tries [22]. Patient demand for treatment may influence the
prescribing behaviors of health care providers. This may
be especially true at the primary health care level where-
working conditions are sometimes unfavorable due toTable 3 Patient-care indicators stratified by anti-malarial med
ASP n (%)
N = 1061
Anti-malarial prescribed was fully dispensed 1,028 (96.9
Anti-malarial adequately labeled 34 (3.2%)
Patient adequately informed about the prescribed anti-malarial 510 (48.1%
*Artemether injection.heavy workloads and low salaries. Additionally, it is not in-
frequent that such facilities encounter medication stock
outs, which can lead by necessity to haphazard prescribing
of other anti-malarial drugs (e.g., prescribing artemether
injections for uncomplicated malaria despite the fact that
this is not recommended therapy).
The majority of health care providers in this study re-
quested a laboratory confirmation for malaria before
prescribing treatment. However, among those who were
prescribed ASP, only half were smear positive. Higher
rates were reported in a Kenyan study where nearly 80%
of patients with negative blood smears were prescribed
malaria treatment [23]. This may raise concerns about
Sudanese healthcare worker’s acceptance of laboratory
results. Lack of trust of health care providers in labora-
tory diagnosis could be a factor in overreliance on clin-
ical diagnosis of malaria. In the past, when laboratory
facilities were largely unavailable in rural and remote
areas, presumptive treatment of malaria was widely ac-
cepted. In recent years, however, with the expansion of
health services across the country including the intro-
duction of rapid diagnostic tests, presumptive treatment
is no longer recommended as long as laboratory facilities
are available. Moreover, requesting a laboratory investi-
gation without utilizing its result is a waste of resources
and poses unnecessary cost for patients. Most import-
antly, prescribing ACT for malaria negative patients in-
creases the risk of developing drug resistance in the
future, and should therefore be restricted. Unless all ef-
forts come together to ensure accurate and safe diagno-
sis of malaria patients, barriers to effective clinical
practices are likely to remain.
According to the national malaria treatment policy,
the first-line treatment is made available free of chargeication prescribed
ART* n (%) All prescriptions n (%) 95% CI Chi-squared
p value
N = 114 N = 1175
%) 104 (91.2%) 1,132 (96.3%) 95.1-97.3 0.006
0 (0.0%) 34 (2.9%) 2-3.9 0.069
) 64 (56.1%) 574 (48.9%) 46-51.8 0.115
Table 4 Supplementary indicators stratified by anti-malarial medication prescribed
ASP n (%) ART* n (%) All prescriptions n (%) 95% CI Chi-squared p value
N = 1,061 N = 114 N = 1,175
Patient presented with history of fever 891 (84.0%) 90 (78.9%) 981 (83.5%) 81.4-85.6 0.184
Patient clinically examined 221 (20.8%) 28 (24.6%) 249 (21.2%) 18.9-23.5 0.338
Peripheral blood smear for malarial obtained 1,029 (97.0%) 105 (92.1%) 1,134 (96.5%) 95.5-97.6 0.013
Peripheral blood smear positive for malaria 516 (50.1%) 73 (69.5%) 589 (51.9%) 49-54.8 0.000
Patient correctly diagnosed with uncomplicated malaria 425 (40.1%) 56 (49.1%) 481 (40.9%) 38.1-43.7 0.071
*Artemether injection.
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ACT using the generic name was widely neglected. Pre-
scribers tend to use the term “Rajimat” to refer to the
first–line therapy instead of prescribing it generically. It
appears that the system for reviewing written prescrip-
tions is either lacking or ineffective. Furthermore, the
rate of antibiotic co-prescribing is evidently high. In
some cases the healthcare provider may be uncertain
about the diagnosis and therefore prescribe an antibiotic
along with the anti-malarial. Haphazard antibiotic pre-
scribing promotes the development of drug resistance
and puts patients at risk of adverse drug effects. Our in-
vestigation also showed that the ACT dosage form was
incorrectly written in the majority of prescriptions. For a
prescription to be considered correctly written it should
at minimum contain the medication’s dose (written in
milligrams), quantity, and schedule. That information
was incorrect, incomplete, or not written in the vast ma-
jority of prescriptions reviewed in our study. This prac-
tice has serious implications related to patient safety,
including increasing the potential for treatment failure,
promoting drug resistance, and increasing the risk of
complications either due to the disease itself or to the
administering of an inappropriate dose.
Interestingly, the availability of ACT in the study sites
was high during the study period. Most ACT prescriptions
were fully dispensed. This is a positive finding, since reli-
able availability of first-line therapies at primary health fa-
cilities would be expected to promote their rational use.
However, labeling of dispensed drug packages was grossly
inadequate. Moreover, information given to patients about
their prescribed treatment was insufficient in most cases.
Patient education and information enhance their adher-
ence to prescribed therapies, leading to better treatment
outcomes [24-26]. Heavy patient load in primary health fa-
cilities could be a main contributory factor.
Given that a multifactorial etiology is likely the cause
for poor ACT prescribing patterns among health
workers in Sudan, it would seem difficult to signifi-
cantly improve the situation unless collaborative efforts
take place by many different stakeholders. Examples of po-
tentially important interventions include targeted training
programmes for health workers, strategies for providingclear ACT information to patients and to the general pub-
lic, strict policies focused on ACT deployment, and con-
tinuous monitoring of existing practices. Clear regulations
relating to ACT use should be institutionalized, and more
support is needed to encourage health care providers to
adhere to the recommended guidelines. Evidence-based
interventions such as implementing a self-administered
checklist have proven to be effective for improving the
performance of health care providers in disciplines such as
surgery and childbirth [27,28]. Perhaps similar checklist-
based interventions could promote the rational use of
ACTs in Sudan.
This study has a several limitations. Prescribing data
in this study were collected prospectively over a limited
period of time and the fact that healthcare providers
were aware that their practices were being observed
could be a source of bias via the Hawthorne effect. How-
ever, retrospective collection of information was not
feasible in this setting since records in most health facil-
ities are severely incomplete. Interruptions in the anti-
malarial drug supply chain or seasonality were also pos-
sible sources of bias. Another limitation of this study is
the cluster sampling method used. While it is a well-
accepted statistical method for increasing efficiency of
data capture, similarities between individuals within
clusters could result in the study sample being less rep-
resentative of the study population. Nevertheless, Gezira
state covers a huge geographical area and random sam-
pling was impractical.Conclusion
The results of this study suggest that poor anti-malarial
prescribing practices are prevalent in Sudan. This has im-
portant public health implications since failure to adhere
to nationally recommended guidelines could play a role in
the development of drug resistance. As such, there may be
urgent need for identifying ways to improve the anti-
malarial prescribing practices of heath workers in Sudan.
Understanding the specific behaviors of health workers,
such as those highlighted in this investigation, may help to
provide a blueprint for how to tailor quality improvement
interventions that will be successful.
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